Franklin Resources’s enGene Therapeutics ENGN Stock Holding History

Franklin Resources’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.96M	Sell	1,314,993 -73,007	-5%	-$650K	﹤0.01%	1283
2025 Q4	$12.5M	Buy	1,388,000 +350,000	+34%	+$2.8M	﹤0.01%	1093
2025 Q3	$7.09M	Hold	1,038,000	–	–	﹤0.01%	1289
2025 Q2	$3.78M	Sell	1,038,000 -136,866	-12%	-$514K	﹤0.01%	1470
2025 Q1	$5.26M	Sell	1,174,866 -15,086	-1%	-$93.7K	﹤0.01%	1324
2024 Q4	$7.91M	Hold	1,189,952	–	–	﹤0.01%	1195
2024 Q3	$9.19M	Buy	1,189,952 +389,918	+49%	+$2.9M	﹤0.01%	1158
2024 Q2	$7.54M	Buy	800,034 +34	+0%	+$436	﹤0.01%	1175
2024 Q1	$13.6M	Buy	+800,000	New	+$9.79M	﹤0.01%	979

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Franklin Resources's ENGN Position: Q1 2026 in Review

Franklin Resources reduced its enGene Therapeutics (ENGN) stake by 5.3% in Q1 2026, selling an estimated $650K and leaving 1,314,993 shares worth $8.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1283.

Franklin Resources first reported a position in ENGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $13.6M in Q1 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Franklin Resources held 1,314,993 shares of enGene Therapeutics worth $8.96M as of Q1 2026.
Franklin Resources sold 73,007 enGene Therapeutics shares in Q1 2026, an estimated $650K.
enGene Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #1283 holding.
Franklin Resources first reported a position in enGene Therapeutics in Q1 2024 and has held it in 9 quarters since.
Franklin Resources's enGene Therapeutics position peaked at $13.6M in Q1 2024.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.